Anu`s Laboratories Limited
Add to watch list to get report alerts
BSE Code:
532981
NSE Code:
Business Profile
Business Profile
Anu`s Laboratories, incorporated on Feb. 20, 1995, is engaged in the manufacture of basic and advanced intermediates and fine chemicals for various drug manufacturers. The company has been promoted by K. Hari Babu and N.S. Walimbe, and other promoter group companies include Nitya Laboratories, Zen Chemi Consultech and Zen Adsorptions.
The ISO 9001:2000 certified company offers products such as 2,4-Di-Chloro-5-
Fluoro Acetophenone (DCFA), an intermediate for synthesizing quinolone antibiotics like ciprofloxacin; Chlorohexanone, Methyl-4 (4-Chloro 1 Oxo Butyl), a di-methyl acetate and poly aluminum chloride; and 1,3-Dibromo Propane among other products. The manufacturing unit is located in the Mahboobnagar district of Andhra Pradesh.
A team of 25 chemists is engaged in research and development at the company`s in-house R&D facilities, which is recognized by Government of India, Department of Scientific & Industrial Research (DSIR). It has a presence in custom synthesis and contract research which encompasses process development and scaling up technologies in pilot plants. Active pharmaceutical intermediates and intermediates like diltiazem, pentoxyfiline, ciprofloxacin, fexofenadine, iopamidol and naproxen have been developed in-house.
The client list includes Dr.Reddy`s Laboratories, Sun Pharmaceuticals, Aurobindo Pharma, Matrix Laboratories, Neuland Laboratories, Suven Life Sciences, Divi`s Laboratories, Hetero Labs, Rallis India, Hiran Orgochem, Ballarpur Industries, Hikal, Delta Paper Mills, Jubilant Organosys, Nicholas Piramal India, Chemspec Chemicals and Sreepathi Pharmaceuticals. Exports account for nearly 20% of total sales. Major export destinations include Israel, Italy, Japan, France, USA and Singapore to client like Teva, Tanabe Research Laboratories, Sanofi-aventis and Mitsui.
The registered office is located at A-49, Madhura Nagar, Vengalrao Nagar, Hyderabad - 500 038.
Recent Developments
04-JUN-09
The company announced its plan to raise additional funds worth Rs 2.50 billion by way of issue of debt, equity or any other security.
Future Plans
The company plans to use the proceeds from the initial public offering (IPO) to part finance its expansion plans of setting up a new plant for the manufacture of drug intermediates including active pharmaceutical ingredients at Vishakhapatnam at an estimated cost of Rs 550.9 million and set up a pilot plant for carrying out contract research and manufacturing at Vishakhapatnam at an estimated cost of Rs 83.4 million. The long term working capital requirements would be Rs 166.7 million.